Abstract:Background: Mycoplasma pneumoniae pneumonia (MPP) causes flu-like symptoms in children, increasing the burden on the health and education systems. In China, traditional Chinese medicine oral liquids (TCMOLs) combined with azithromycin (TCMOLs + Azithromycin) is commonly used to treat MPP in children. However, TCMOLs with the optimal clinical applicability remain unknown. Here, we evaluated the clinical effectiveness and safety of TCMOLs + Azithromycin in children with MPP. Methods: We searched PubMed, Embase, Cochrane Library, Ovid, Web of Science, China National Knowledge Infrastructure (CNKI), Wanfang Data Knowledge Service Platform, and VIP information resource integration service platform databases for eligible randomized controlled trials (RCTs) published from database inception to October 2020. Two reviewers independently performed data extraction and risk of bias assessment. After Bayesian random effect modeling and surface under the cumulative ranking curve (SUCRA) scoring, we ranked each intervention. We assessed heterogeneity using multivariate meta-regression for potential modifiers and used the Grading of Recommendations, Assessment, Development, and Evaluation to rate pooled evidence’s certainty. Results: In the 63 included RCTs with 6,410 children, five different TCMOLs were combined with azithromycin. TCMOLs + Azithromycin had significantly better primary outcomes than did azithromycin alone. Of all TCMOLs, Xiaoer Xiaoji Zhike (XEXJZK)+Azithromycin showed the best effectiveness with respect to the response rate (odds ratio [OR] = 6.5, 95% credible interval [CrI] = 4.3–10; low certainty) and pulmonary rales disappearance time (mean difference [MD] = −2.1, 95% CrI: −2.9 to −1.2; low certainty) with SUCRA 85 and 80%, respectively. Pudilan Xiaoyan + Azithromycin showed the highest effectiveness with respect to cough disappearance time (MD = −2.6, 95% CrI: −3.4 to −1.7; very low certainty) and fever disappearance time (MD = −1.8, 95% CrI: −2.3 to −1.3; very low certainty) with SUCRA 87 and 87%, respectively. The difference in the adverse effects between TCMOLs + Azithromycin and azithromycin alone was nonsignificant. Conclusion: Of the different TCMOLs, XEXJZK may be the best option to combine with azithromycin to treat children with MPP. However, our results should be interpreted with caution due to the low certainty of evidence. In general, TCMOLs’ safety remains unclear because of a lack of evidence. More high-quality RCTs are needed to further evaluate efficacy and safety of these TCMOLs.

Clinical Observation of Aerosol Inhalation of Azithromycin Combined with Budesonide Suspension in the Treatment of Mycoplasma Pneumoniae Pneumonia in Children.

Azithromycin Sequential Therapy Combined with Nebulization Inhalation of Budesonide and Combivent in Treating Mycoplasma Pneumonia in 40 Children Cases

Meta-analysis of combined azithromycin and inhaled budesonide treatment for Chinese pediatric patients with mycoplasma pneumonia

Acetylcysteine and budesonide for the treatment of refractory Mycoplasma pneumoniae pneumonia in children: a clinical observation

Effect of Ambroxol Hydrochloride and Clenbuterol Hydrochloride Tablets Combined with Azithromycin Intervention on Anti-Inflammatory,proinflammatory Cytokines and Immune Function in Children with Mycoplasma Pneumonia

Study on the Therapeutic Effect of Azithromycin Combined with Glucocorticoid on Pulmonary Function and Inflammatory Response in Children with Pneumonia

Clinical Efficacy of Azithromycin in Treatment of Children’s Mycoplasma Pneumonia

The Effect of Azithromycin in Treating Mycoplasma Pneumonia in Children

Comparison of azithromycin and erythromycin in the treatment of mycoplasma pneumonia in children

Azithromycin sequential therapy plus inhaled terbutaline for Mycoplasma Pneumoniae pneumonia in children: a systematic review and meta-analysis

Efficacy and safety of azithromycin combined with glucocorticoid on refractory Mycoplasma pneumoniae pneumonia in children

Effect of azithromycin combined with ambroxol in children with Mycoplasma pneumoniae pneumonia

Analysis of the Efficacy of Erythromycin Cyclic 11,12-Carbonate Combined with Azithromycin in the Treatment of Severe Mycoplasma Pneumoniae Pneumonia in Children and its Effect on Cytokines

Efficacy of Azithromycin plus Glucocorticoid Adjuvant Therapy on Serum Inflammatory Factor Levels and Incidence of Adverse Reactions in Children with Mycoplasma Pneumonia

Traditional Chinese Medicine Oral Liquids Combined With Azithromycin for Mycoplasma pneumoniae Pneumonia in Children: A Bayesian Network Meta-Analysis

Clinical Efficacy of Ulinastatin Combined with Azithromycin in the Treatment of Severe Pneumonia in Children and the Effects on Inflammatory Cytokines and Oxidative Stress: A Retrospective Cohort Study

The change of asthma-associated immunological parameters in children with mycoplasma pneumoniae infection

Effect of Methylprednisolone Plus Azithromycin on Fractional Exhaled Nitric Oxide and Peripheral Blood Eosinophils in Children with Refractory Mycoplasma Pneumoniae Pneumonia

Shuanghuanglian oral preparations combined with azithromycin for treatment of Mycoplasma pneumoniae pneumonia in Asian children: A systematic review and meta-analysis of randomized controlled trials

Clinical Efficacy of Azithromycin in the Treatment of Pediatric Mycoplasma pneumoniae Pneumonia and Its Impact on Platelet Count and D-Dimer Levels

The Timing Of Azithromycin Treatment Is Not Associated With The Clinical Prognosis Of Childhood Mycoplasma Pneumoniae Pneumonia In High Macrolide-Resistant Prevalence Settings